文献速递肝病

抑制钠-葡萄糖协同转运蛋白2与糖尿病患者肝脏相关并发症:孟德尔随机化与人群队列研究

Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study.
PubMed 文献 · Hepatology · 2024-03-11

研究采用孟德尔随机化(UK Biobank与FinnGen数据)及韩国全国人群队列,评估SGLT2抑制剂对肝脏相关结局的影响。结果显示SGLT2抑制与肝硬化发生风险降低相关,且SGLT2i组肝脏相关并发症风险显著低于DPP-4i组。

要点

  • 基于6个SNP的遗传风险评分孟德尔随机化显示,SGLT2抑制与肝硬化风险降低相关。
  • 韩国NHIS队列中,SGLT2i组肝脏相关并发症风险显著低于DPP-4i组。
  • 敏感性分析中SGLT2i组风险降低始终显著。

核心结论

  • 基于两个欧洲队列的孟德尔随机化及韩国全国人群队列研究均提示,SGLT2抑制与肝脏相关事件风险降低相关。

研究设计与样本

  • 利用UK Biobank数据(n=337,138)构建遗传风险评分,并进行两样本孟德尔随机化(FinnGen n=218,792与UK Biobank)。
  • 平行开展基于韩国国民健康保险服务(NHIS)数据库的全国人群研究,比较SGLT2i组(n=13,208)与倾向性评分匹配的DPP-4i组(n=70,342)。

主要发现

  • 基于遗传风险评分的孟德尔随机化显示,SGLT2抑制(遗传风险评分每增加1个标准差,HbA1c降低0.1%)与肝硬化发生风险呈负相关(校正比值比=0.83,95%CI=0.70-0.98,p=0.03)。
  • 两样本孟德尔随机化结果一致(比值比=0.73,95%CI=0.60-0.90,p=0.003)。
  • 韩国NHIS数据库中,SGLT2i组肝脏相关并发症风险显著低于DPP-4i组(校正风险比=0.88,95%CI=0.79-0.97,p=0.01)。
  • 多种敏感性分析中该差异始终显著(校正风险比=0.72-0.89,所有p<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: No medication has been found to reduce liver-related events. We evaluated the effect of sodium-glucose cotransporter-2 inhibitor (SGLT2i) on liver-related outcomes. APPROACH AND RESULTS: Single nucleotide polymorphisms associated with SGLT2 inhibition were identified, and a genetic risk score (GRS) was computed using the UK Biobank data (n=337,138). Two-sample Mendelian randomization (MR) was conducted using the FinnGen (n=218,792) database and the UK Biobank data. In parallel, a nationwide population-based study using the Korean National Health Insurance Service (NHIS) database was conducted. The development of liver-related complications (ie, hepatic decompensation, HCC, liver transplantation, and death) was compared between individuals with type 2 diabetes mellitus and steatotic liver diseases treated with SGLT2i (n=13,208) and propensity score-matched individuals treated with dipeptidyl peptidase-4 inhibitor (n=70,342). After computing GRS with 6 single nucleotide polymorphisms (rs4488457, rs80577326, rs11865835, rs9930811, rs34497199, and rs35445454), GRS-based MR showed that SGLT2 inhibition (per 1 SD increase of GRS, 0.1% lowering of HbA1c) was negatively associated with cirrhosis development (adjusted odds ratio=0.83, 95% CI=0.70-0.98, p =0.03) and this was consistent in the 2-sample MR (OR=0.73, 95% CI=0.60-0.90, p =0.003). In the Korean NHIS database, the risk of liver-related complications was significantly lower in the SGLT2i group than in the dipeptidyl peptidase-4 inhibitor group (adjusted hazard ratio=0.88, 95% CI=0.79-0.97, p =0.01), and this difference remained significant (adjusted hazard ratio=0.72-0.89, all p <0.05) across various sensitivity analyses. CONCLUSIONS: Both MRs using 2 European cohorts and a Korean nationwide population-based cohort study suggest that SGLT2 inhibition is associated with a lower risk of liver-related events.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Chung SW, Moon HS, Shin H, et al. Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study. Hepatology. 2024. PMID: 38466796. doi:10.1097/HEP.0000000000000837

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。